Nuzenio

Repatha Use

Repatha Use news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Timeline

Sat, 08 Aug 2026 11:46:03 GMTAmgen (AMGN) Is Up 6.7% After EMA Backs Broader Repatha Use in High-Risk Patients – Has The Bull Case Changed? - simplywall.st
Wed, 05 Aug 2026 01:51:57 GMTAmgen remains bullish on Repatha, axes obesity asset in 2Q report - FirstWord Pharma
Fri, 31 Jul 2026 03:38:35 GMTHow Investors May Respond To Amgen (AMGN) Repatha Expansion and 2026 Dividend Declaration - simplywall.st
Thu, 30 Jul 2026 14:31:43 GMTAmgen’s Repatha receives positive CHMP opinion for broader cardiovascular use - Pharmaceutical Business review -
Wed, 29 Jul 2026 15:29:08 GMTEuropean Medicines Agency Supports Amgen's Repatha for Broader Use - Intellectia AI
Wed, 29 Jul 2026 07:00:00 GMTPOSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE - Amgen

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Repatha Use.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.